The Effect of Entecavir Therapy on Immune Status in Chronic Hepatitis B Patients

Huimin Yan¹*, Xinyu Zhang², Ying Lv³

¹Clinical Research Center, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei 050021, ²Graduate College of Hebei Medical University, Hebei Medical University, Shijiazhuang, Hebei 050017, ³Clinical Research Center, Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei 050021, China

ABSTRACT

Background: Entecavir (ETV) is an antiviral medication effective in suppressing hepatitis B virus (HBV) replication and improving liver function. However, the relationship between antiviral effect and immune modulation after ETV therapy is not clearly understood. Objective: The objective of this study is to investigate the immunoregulatory effect of ETV treatment in patients with chronic hepatitis B (CHB). Methods: The frequencies of immune cells, including IFN-γ-producing CD4+ and CD8+ T cells, Th9 cells, regulatory T (Treg) cells, and myeloid-derived suppressor cells (MDSC) were determined in the peripheral blood from treatment-naïve and ETV-treated CHB patients. The plasma levels of IL-10, TGF-β, IL-9, TNF-α, IFN-γ, and Arg-1 were measured using enzyme-linked immunosorbent assay. Results: The results showed that ETV treatment significantly reduced the levels of liver function indices as well as HBV DNA loads in CHB patients. However, no significant difference in the immune cells percentage was found between the treatment-naïve and ETV-treated patients. Additionally, ETV treatment did not influence the production of TGF-β, IL-9, Arg-1, IFN-γ, and TNF-α. In contrast, the level of IL-10 was remarkably reduced after ETV therapy. Conclusion: IL-10 was a more sensitive effector to ETV-induced inhibition of HBV replication in chronic HBV patients.


Keywords: Chronic Hepatitis B, Cytokine, Entecavir, Immune Cells

*Corresponding author: Dr. Huimin Yan, Clinical Research Center, Shijiazhuang Fifth Hospital, 42 Tanan Road, Shijiazhuang, Hebei 050021, China, e-mail: yanhm2538@163.com
INTRODUCTION

Infection with the hepatitis B virus (HBV) affects large numbers of individuals worldwide with a high risk of developing severe liver disease (1). Accumulated evidence has demonstrated that HBV is not directly cytopathic; rather, the main cause of the development of hepatitis B is an inappropriate host immune response to virus-infected hepatocytes (2,3). Therefore, the improvement in immune status is closely associated with the outcome of hepatitis B patients.

Currently, nucleoside/nucleotide analogs (NAs) have been widely provided for clinical use to treat chronic HBV infection. NAs are highly effective inhibitors of viral replication, which can selectively suppress the activity of HBV DNA polymerase (4). Of these NAs, Entecavir (ETV) is a relatively new agent that is recommended as first-line therapy by clinical practice guidelines (5). The treatment efficacy of ETV is excellent in suppressing HBV DNA and delaying disease progression (6). However, it rarely cures HBV infection because ETV alone cannot completely eliminate intracellular virus (7). It is well known that the complete eradication of HBV depends on effective anti-viral immune response, including multiple immune cells and their related cytokines (8,9). Therefore, understanding the immunomodulatory effect of ETV may provide useful information about the development of a novel immunotherapeutic approach. Despite several studies have conducted in this research field, the results are inconsistent (10-12). Moreover, several new types of immune cells, such as myeloid-derived suppressor cells (MDSC) and Th9 cells, have been recently discovered. Overall, limited information is available about the effects of ETV on these cells.

In the present study, the potential immunoregulatory properties of ETV were assessed with a high emphasis on the effects on IFN-γ-producing T cells, MDSC, regulatory T (Treg) and Th9 cells, and their related cytokines. We focused on evaluating the expression of immune cells and cytokines in peripheral blood. Although analyzing their levels in the liver could better reflect the host immune status, it is difficult to develop and implement in clinical practice due to the relative inaccessibility of liver tissue. Recently, increasing evidence has suggested the impact of peripheral immune responses on disease progression in the chronic HBV infection (13). Our results will help better understand the inadequate capacity of ETV in improving immune function and provide new ideas for researching how to further promote the therapeutic effect.

MATERIALS AND METHODS

Patients. Between August 2015 and October 2016, 38 CHB patients were recruited from Shijiazhuang Fifth Hospital, China. Among the patients, 22 were NAs-naïve patients who had never received NAs and interferons treatment and 16 were ETV-treated patients who had been treated with ETV (0.5 mg/d) for 24 weeks. The mean age of the patients was 41.05 ± 13.85 years. Of the total study population, 77.27% (17) were male in the NAs-naïve group, whereas the mean age was 42.87 ± 10.43 years, and 62.5% (10) were male in the ETV-treated group. All patients were diagnosed according to the Guideline of Prevention and Treatment for Chronic Hepatitis B in China (2010 version). Patients coinfected with hepatitis virus A, C, D, E, human immunodeficiency virus (HIV), acute hepatitis B, alcoholic, or drug-induced liver injury were excluded. The study was approved by the Shijiazhuang Fifth Hospital Ethics Committee.
Isolation of peripheral blood mononuclear cells. Peripheral blood mononuclear cells (PBMCs) were isolated by ficoll density gradient centrifugation. Briefly, peripheral blood was collected into EDTA-coated tubes and mixed with the same volume of PBS. Diluted blood was carefully added to human lymphocyte separation medium (Solarbio Science & Technology, Beijing, China). After centrifugation, the interphase containing mononuclear cells was obtained. The cells were washed 3 times with RPMI 1640 and resuspended in culture medium.

Flow cytometric analysis. For MDSC examination, 200 μL of whole blood sample was stained with the following monoclonal antibodies: CD11b-APC, CD33-PE, and HLA-DR-PE/Cy7 (all from BioLegend, San Diego, CA, USA). After incubation for 15 min, each sample was treated with 1 mL of lysing solution (Beckman Coulter, Miami, FL, USA) for 10 min. To stain intracellular cytokines, PBMCs were stimulated with phorbol-12-myristate 13-acetate (50 ng/mL) and ionomycin (1 μg/mL). Meanwhile, GolgiStop (Becton Dickinson, San Diego, CA, USA) was added to each well and treated for 4 h at 37°C. After harvesting, the cells were stained with CD4-FITC and CD8a-PerCP/Cy5.5 (all from BioLegend, San Diego, CA, USA), fixed and permeabilized with Fixation and Permeabilization solution (Becton Dickinson, San Diego, CA, USA), and then were intracellularly stained with IFN-γ-PE/Cy7 and IL-9-PE (BioLegend, San Diego, CA, USA). For Treg cell examination, PBMCs were surface stained with CD4-FITC and CD25-APC (all from BioLegend, San Diego, CA, USA) for 20 min, and then fixed and permeabilized with Fixation and Permeabilization Solution (eBioscience, San Diego, CA, USA), followed by staining with Foxp3-PE (BioLegend, San Diego, CA, USA). All samples were detected by FACS CantoII flow cytometer and analyzed by FACS Diva software.

Enzyme-linked immunosorbent assay (ELISA). Plasma samples were collected, and the levels of IL-10, TGF-β, TNF-α, IL-9, IFN-γ, and Arg-1 were measured using human ELISA assay kits (Multi Sciences, Hangzhou, Zhejiang, China) according to the manufacturer’s instructions. The optical density (OD) at 450nm was measured by a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA).

Biochemical and virological assessments. The biochemical indices, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL), were measured using an automated analyzer with standard techniques. Serum HBV DNA load was detected by real-time PCR using an ABI7500 quantitative PCR instrument (Applied Biosystems, Foster City, CA, the USA), where the lowest detection limit was 500 copies/mL.

Statistical analysis. All statistical analyses were performed using SPSS 19.0 software (SPSS Inc, Chicago, IL, USA). Data were expressed as mean ± SD or median with range. The comparison of differences between each group was analyzed using Student’s t-test, Mann-Whitney U test, or Chi-square test. Pearson correlation tests were done for correlation analysis. A two-sided P value of <0.05 was considered to be statistically significant.

RESULTS

Antivirus efficacy of ETV treatment. After treatment with ETV for 24 weeks, the levels of ALT and AST were significantly decreased (P<0.05). The proportion of ALT
and AST normalization was 81.25% and 87.50%, respectively. Additionally, treatment with ETV led to a significant decline in HBV-DNA loads (P<0.05) (Table 1).

**Table 1. Demographic and clinical characteristics of study subjects.**

<table>
<thead>
<tr>
<th></th>
<th>NAs-naïve patients (n=22)</th>
<th>ETV-treated patients (n=16)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT (U/L, median with range)</td>
<td>56.50 (17.00, 903.00)</td>
<td>36.00 (19.00, 55.00)</td>
<td>0.006</td>
</tr>
<tr>
<td>AST (U/L, median with range)</td>
<td>54.00 (18.00, 211.00)</td>
<td>27.00 (18.00, 70.00)</td>
<td>0.005</td>
</tr>
<tr>
<td>TBIL (mg/dl, median with range)</td>
<td>1.14 (0.53, 15.32)</td>
<td>1.05 (0.58, 2.28)</td>
<td>0.328</td>
</tr>
<tr>
<td>DBIL (mg/dl, median with range)</td>
<td>0.56 (0.23, 11.11)</td>
<td>0.37 (0.18, 0.82)</td>
<td>0.319</td>
</tr>
<tr>
<td>HBV DNA loads (log₁₀ copies/mL, median with range)</td>
<td>6.17 (2.70, 8.22)</td>
<td>2.70 (2.70, 2.87)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**The effect of ETV treatment on the percentage of immune cells.** We first investigated the effect of ETV treatment on two types of immunosuppressor cells, including MDSC and Foxp3+ cells. The results showed that there was no significant difference between NAs-naïve patients and ETV-treated patients (P>0.05) (Figure 1). Moreover, compared with NAs-naïve patients, ETV-treated patients had slightly lower frequencies of IFN-γ-producing CD4+ and CD8+ cells, and slightly higher percentage of IL-9-producing CD4+ cells, but without any significant difference (P>0.05) (Figure 1).

![Figure 1. Effect of ETV treatment on the percentage of immune cells.](image-url)
The effect of ETV treatment on cytokine production. After ETV treatment, the level of IL-10 was significantly decreased in the ETV-treated patients compared to those NAs-naive patients (P<0.05) (Figure 2). However, there was no significant difference between the two groups in the production of other cytokines, including TGF-β, IL-9, Arg-1, IFN-γ, and TNF-α (P>0.05) (Figure 2).

![Figure 2. Effect of ETV treatment on the production of cytokines.](image)

IL-10 is a critical immunoregulatory cytokine, which is known to play key roles in the pathogenesis of CHB (14,15). Moreover, it plays a major impact on the downregulation of other immune cells. Thus, the relationship of IL-10 levels with the percentage of immune cells in ETV-treated patients was analyzed. However, there was no strong correlation between the levels of IL-10 with the frequencies of MDSC, Foxp3+ cells, IFN-γ-producing CD4+, and CD8+ cells, and IL-9-producing CD4+ cells (P>0.05) (Table 2).

DISCUSSION

ETV has widely been used as a first choice drug for CHB patients because of its low rate of genotypic resistance. Several studies have shown that ETV is a highly potent agent against chronic hepatitis B (5,6). Consistent with the previous works, in this study, we found that treatment with ETV resulted in a significantly improved liver function and had a strong inhibition effect on HBV DNA. This observation supports the conclusion that ETV treatment is effective for HBV DNA suppression.
Considering the impaired cellular immune response in chronic HBV infection, the effect of ETV on immune cells was observed. IFN-γ-producing CD4+ and CD8+ cells are well-known important components of HBV-specific immune response and play important roles in the control of HBV (16). In contrast, Treg cells are negative immunoregulatory cell population that suppress HBV-specific immune responses and indirectly influence the disease progression (17). Despite several previous studies have reported the effect of ETV monotherapy on IFN-γ-producing T cells and Treg cells (10-12,18), the obtained results are inconsistent. In the present study, we demonstrated that there were no significant differences in the frequencies of IFN-γ-producing CD4+ and CD8+ T cells as well as Treg cells between patients with and without ETV treatment, suggesting that ETV therapy failed to restore T cell response.

More recently, the other two immune cells (i.e., MDSC and Th9) have received increasing attention. MDSC are immunosuppressive cells that possess strong inhibitory effects toward innate and adaptive immune response. Increasing evidence has demonstrated that MDSC contributes to the persistent infection of HBV through suppressing the proliferative capacities of allogeneic T cells (19). Th9 cells are newly-discovered subset of T helper cells that are characterized by IL-9 and IL-10 secretion. Our previous study has shown that Th9 cells are negatively correlated with the development of chronic HBV infection in CHB patients (20). However, to date, the effect of antiviral therapy on MDSC and Th9 cells remains unknown. To our knowledge, the present study reports for the first time that ETV treatment did not lead to the change of the frequency of MDSC and Th9 cells. These results, together with the above data, suggest that ETV had little ability to regulate immune cells.

Many cytokines have been suggested to contribute to effective antiviral immunity and the outcome of HBV infection. The effect of ETV on the level of cytokines was also observed. The results showed that IL-10 production was significantly decreased after ETV treatment. However, the levels of other cytokines, including IFN-γ, IL-9, Arg-1, TGF-β, and TNF-α, were not significantly changed. These data suggested that IL-10 was a more sensitive effector associated with ETV treatment. This finding is consistent with that of Yu et al. (21), but different from another study in which the IL-10 level was significantly increased after ETV treatment (22). IL-10 is an important immunoregulatory cytokine involved in suppressing effective immune functions. The reduced IL-10 production after ETV therapy implies that ETV may have a certain role in restoring the impaired immune response, which is helpful for alleviating the disease.

Table 2. The correlation between IL-10 and immune cells in ETV-treated patients.

<table>
<thead>
<tr>
<th></th>
<th>IL-10</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDSC (%)</td>
<td>0.061</td>
<td>0.823</td>
</tr>
<tr>
<td>Foxp3+ Treg cells (%)</td>
<td>-0.438</td>
<td>0.178</td>
</tr>
<tr>
<td>Th9 cells (%)</td>
<td>-0.538</td>
<td>0.109</td>
</tr>
<tr>
<td>IFN-γ-production CD4+ cells (%)</td>
<td>0.207</td>
<td>0.566</td>
</tr>
<tr>
<td>IFN-γ-production CD8+ cells (%)</td>
<td>0.807</td>
<td>0.099</td>
</tr>
</tbody>
</table>
To investigate the immune cells involved in IL-10 reduction, we analyzed the correlation of the level of IL-10 and the frequency of immune cells. In this study, however, no clear correlation was found between IL-10 and any immune cells in ETV-treated patients. It has been well evidenced that IL-10 is produced by various kinds of cells, such as MDSC, Th2, Th9, and Treg cells (23,24). Therefore, we speculate that the reduction of IL-10 level might be due to the decreased secretion capacity of various immune cells. Further studies are needed to investigate the major subsets of immune cells involved in the regulation of IL-10 production when HBV replication was profoundly inhibited by ETV therapy.

The major limitation of this study is that the expression of immune cells and their related cytokines was only determined from two independent cohorts at a single time point, and the dynamical change was not observed. A previous study has found that ETV therapy induces temporary increased Th17 cells and, subsequently, their level declines to the baseline level (25), suggesting that ETV may have a significant short-term and long-term effect on the immune system. The further longitudinal analysis may better clarify the change of the immune system in the process of ETV therapy.

In summary, this study demonstrated that ETV treatment displayed strong antiviral action but weak immunomodulatory property. The ETV-driven improvement of immune response seemed to be only associated with the decreased IL-10 production. Therefore, the development of the combined therapy with ETV and immune modulators may provide more clinical benefit. Currently, there has been an interest in the combined use of NAs and Peg-IFN-α, a cytokine with dual antiviral and immunomodulatory activity, to improve immune function in CHB patients (26). However, clinical use of Peg-IFN-α is limited due to the severe side effects and the contraindication in patients with decompensated liver cirrhosis or autoimmune disease. Hence, further studies should be carried out to develop new immunotherapeutic approaches to restore antiviral immunity and improve clinical efficacy in CHB patients.

ACKNOWLEDGEMENTS

This work was supported by the Hebei Medical Research Foundation (No. 20150893).

REFERENCES


